LuSeed Vascular is a clinical-stage company developing DOME™️, a first-in-class, minimally invasive device for bifurcation and sidewall aneurysms. Addressing key limitations of current treatments, it expands the addressable market by 30%. In a $2.5B market growing at 14% CAGR, LuSeed shows promising clinical data including long term follow up. The company is now focused on ongoing trials and raising Series A to reach IDE approval for pivotal U.S./EU studies.